Ongoing conversations across our research network.
Has anyone validated the SHERLOCK v2 protocol with the new lyophilized reagents? We are seeing inconsistent signal in field samples.
We just submitted our CTIS dossier for a Phase I oncology trial. The new EU CTR portal is actually more intuitive than expected — happy to share our checklist.
Looking for collaborators on a synthetic biology grant — we are engineering P. putida for nylon monomer production. Scale-up data attached.
Updated our internal guidelines on biosafety level 2+ workflows for CRISPR delivery vectors. Comments welcome before final review.
What research teams say about working with our scientific coordination and analytical insight.
“Rivabiotec helped us structure a complex multi-site biomarker study. Their project coordination reduced our timeline by nearly four months and kept every lab aligned on the same protocol.”
Dr. Elena Marchetti
Principal Investigator, Oncodiag Consortium
“The analytical insight Rivabiotec provided on our fermentation data was a game-changer. They identified a critical bottleneck we had missed and suggested a simple media adjustment that boosted yield by 22%.”
James Okonkwo
VP of Bioprocess, Synthia Bio
“We needed a scientific coordinator who could speak both the language of the lab and the language of our investors. Rivabiotec bridged that gap seamlessly, helping us secure a second round of funding.”
Dr. Aisha Voss
CEO, Voss Biotech GmbH
Feedback from scientists and partners we’ve worked alongside.
“Rivabiotec helped us structure our Phase I trial protocol and navigate the regulatory submission. Their scientific coordination saved us at least three months.”
Dr. Elena Marchetti
Principal Investigator, Oncogenix Lab
“The analytical insight we received on our synthetic biology pipeline was precise and actionable. Rivabiotec understands the bench-to-market reality.”
Samuel Okonkwo
Co-founder, BioForge Solutions
“We needed a partner who could speak both the science and the strategy. Rivabiotec delivered clear project structuring and realistic milestones.”
Dr. Aiko Tanaka
Head of R&D, Kyodo BioVentures
Collaborating with
Follow our work in biotechnology consulting, research coordination, and scientific innovation across key platforms.